JUBLPHARMA (Jubilant Pharmova Ltd.): Regulatory Action
Jubilant Pharmova informed the exchange of a Show Cause Notice received by the company relating to GST — a regulatory-action event that is the catalyst behind this note. A show-cause notice is a demand for explanation, not a proven liability, but it is a governance overhang.
Strota's base rate for regulatory-action events is close to a coin toss on a small sample: across 20 past instances, the stock rose 55% of the time with a median edge of about -0.057% — little historical drift either way. That is a pattern across many names on a thin sample, not a forecast for Jubilant Pharmova, and it should be read as context rather than a prediction.
The pack carries a bullish counterweight: it also lists USFDA approval items for the company, which carry a positive bias, so the GST notice sits beside genuine regulatory wins. On valuation, the stock trades at a price-to-earnings multiple of 40.98, a price-to-book of 2.03, earnings per share of 22.14 and a market cap near ₹14,375 crore, with a dividend yield of 0.55%.
The data establishes a GST show-cause notice as the day's bearish event, set against a historically flat base rate on a limited sample and a separate string of USFDA approvals. What it does not establish is the eventual outcome of the notice; the base rate describes the event class, not this specific case, and the final impact depends on how the matter resolves.
The catalyst
Jubilant Pharmova Limited has informed the Exchange about General Updates - Receipt of Show Cause Notice by Jubilant Pharmova Limited - GST (filing · NSE)
What the data shows after this event
Across Strota's backtest of past filings, Regulatory Action shows no reliable next-session edge — the move went bearish in about 55.0% of next sessions (net -0.057% after drift and cost, n=20). A base rate, not a forecast for this stock.
JUBLPHARMA right now
trading +2.91% on the day; P/E 40.98; RSI 39.3. Full JUBLPHARMA analysis →
Sources
- Jubilant Pharmova Limited has informed the Exchange about General Updates - Receipt of Show Cause Notice by Jubilant Pharmova Limited - GST — NSE
- Jubilant Pharmova Ltd. Shareholding Pattern – Promoters, FIIs & DIIs — Value Research
- Jubilant Pharmova Q1 Results: Board Meeting Rescheduled to Aug 10 — scanx.trade
- Jubilant Pharmova subsidiary to appeal Rs 53.37 Cr tax disallowance — scanx.trade
- Jubilant Pharmova Q4 profit declines 21 pc at Rs 119.3 cr — pharma.economictimes.indiatimes.com
Keep digging
- JUBLPHARMA — full smart-money page: F&O positioning, deals, insider filings and option chain in one place.
- Today's screens: every stock matching the same setups (buildups, breakouts, volume shockers).
- Newsroom: the other stocks in play this session.